GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Cirrhosis Liver/Falls in Cirrhosis - Prior Falls and Frailty Identify Patients at Highest Risk: Hepatology Communications | September 2026
1

Falls in Cirrhosis - Prior Falls and Frailty Identify Patients at Highest Risk: Hepatology Communications | September 2026

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated September 1, 2026

What Did the Study Find?

This large CAPriCORN multicenter study evaluated 42,046 patients with cirrhosis over a mean follow-up of approximately 3.4 years to identify predictors of falls and recurrent falls.

  • 7.1% of patients experienced a fall, including 2.6% within the first year after cirrhosis diagnosis.
  • Previous fall history was the strongest predictor of another fall (HR 5.69).
  • Frailty independently increased fall risk:
  • Severe frailty: HR 2.37
  • Intermediate frailty: HR 1.71
  • Importantly, 38.4% of patients who fell experienced another fall during follow-up.
  • Among patients with recurrent falls, 35% experienced another fall within one year.
  • Previous falls (HR 1.50) and severe frailty (HR 1.51) were the strongest predictors of a second fall.
  • Patients with severe frailty had a 10-year cumulative fall incidence of 19.6%.

Why Does It Matter?

Falls are often overlooked during routine cirrhosis assessment, despite their potential consequences, including fractures, hospitalization, functional decline and loss of independence.

This study demonstrates that fall risk is not determined simply by age or liver disease severity. Prior falls and measurable frailty provide clinically useful information for identifying vulnerable patients.

GastroAGI Takeaway

In every cirrhosis clinic, ask one simple question: “Have you fallen in the past year?”

A previous fall identifies a particularly high-risk patient, while frailty further increases the likelihood of both first and recurrent falls.

These findings support incorporating routine fall-history assessment, frailty screening, medication review, nutritional optimisation, and balance/strength interventions into comprehensive cirrhosis care.

The clinical implication is especially relevant alongside the recent LiveSMART randomised trial, which reported fewer falls with lactulose followed by TeleTai-Chi in selected patients with cirrhosis.

Related Q&A

02

A 7-mm TIPS Halved Encephalopathy Risk Without Sacrificing Rebleeding Control: Liver International | October 2026

What Did the Study Find? Investigators randomised 184 patients with cirrhosis, previous variceal bleeding, and a relatively small liver to covered TIPS created with a 7-mm or 8-mm...

03

Cirrhosis Natural History: After the First Decompensation, the Disease Trajectory Accelerates: Hepatology Communications | October 2026

What Did the Study Find? This CORE Consortium study followed 1,777 patients with compensated advanced chronic liver disease (cACLD), defined by liver stiffness ≥15 kPa, across 19 international...

04

Cirrhosis Care Should Become a Preventive Bundle—not a Series of Rescue Interventions: AJG | October 2026

What Did the Guideline Find? The new ACG guideline translates preventive cirrhosis care into 18 GRADE-assessed recommendations and six key concepts spanning cirrhosis-specific complications, infection prevention, lifestyle interventions...

05

TIPS Beyond Conventional Indications: Encouraging Data in HRS-AKI, but Patient Selection Remains Critical: Scientific Reports | September 2026

What Did the Study Find? This multicenter Asia-Pacific study evaluated 207 patients undergoing technically successful TIPS across six centres, including high-risk populations with HRS-AKI, CKD and ACLF. s41598-026-70413-9_reference...

06

Portal Vein Thrombosis in Cirrhosis: A Marker of Higher Short-Term Mortality: Liver Transplantation | September 2026

What Did the Study Find? The multinational CLEARED Consortium prospectively evaluated 7,721 non-electively hospitalised patients with cirrhosis, providing large-scale global data on portal vein thrombosis (PVT). PVT was...

07

Beyond West Haven: Can mHEST Make Hepatic Encephalopathy Staging More Objective?: CGH | September 2026

What Did the Study Find? The study evaluated the modified Hepatic Encephalopathy Staging Tool (mHEST) as a more objective alternative to conventional West Haven criteria. Among 49 clinicians...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer